Qiagen N.V. (NYSE:QGEN) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Qiagen N.V. has received a consensus recommendation of "Hold" from 11 analysts, with eight suggesting a hold and three a buy.
• Bank of America raised its price target for Qiagen shares from $50.00 to $53.00 while maintaining a "buy" rating.
• The company reported earnings of $0.60 per share for the last quarter, in line with analysts' estimates, alongside a 7.7% increase in revenue year-over-year.

Shares of Qiagen N.V. (NYSE:QGEN - Get Free Report) have been assigned an average rating of "Hold" from the eleven analysts that are presently covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $49.6865.

A number of brokerages have issued reports on QGEN. Bank of America increased their price objective on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Cowen reaffirmed a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a research report on Monday, August 11th. Barclays started coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Finally, UBS Group raised their price target on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th.

Qiagen Trading Down 0.1%

Shares of QGEN stock opened at $49.1340 on Friday. Qiagen has a 52-week low of $37.63 and a 52-week high of $51.88. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm has a market capitalization of $10.92 billion, a PE ratio of 29.03, a PEG ratio of 2.58 and a beta of 0.64. The stock has a fifty day simple moving average of $48.56 and a two-hundred day simple moving average of $43.85.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.60. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The firm had revenue of $533.54 million during the quarter, compared to analysts' expectations of $523.97 million. During the same quarter last year, the business posted $0.55 earnings per share. The firm's revenue was up 7.7% on a year-over-year basis. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

Qiagen Dividend Announcement

The firm also recently announced a dividend, which was paid on Thursday, July 10th. Investors of record on Thursday, July 3rd were issued a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 52.0%. Qiagen's dividend payout ratio (DPR) is 14.79%.

Hedge Funds Weigh In On Qiagen

A number of institutional investors and hedge funds have recently made changes to their positions in QGEN. Wells Fargo & Company MN grew its stake in shares of Qiagen by 31.8% in the 4th quarter. Wells Fargo & Company MN now owns 66,779 shares of the company's stock worth $2,974,000 after buying an additional 16,106 shares in the last quarter. Commerce Bank grew its position in Qiagen by 20.4% in the fourth quarter. Commerce Bank now owns 5,931 shares of the company's stock worth $264,000 after acquiring an additional 1,004 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Qiagen by 23.6% in the 4th quarter. MetLife Investment Management LLC now owns 29,572 shares of the company's stock worth $1,318,000 after purchasing an additional 5,637 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Qiagen by 770.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock worth $111,000 after purchasing an additional 2,204 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Qiagen by 23.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 142,794 shares of the company's stock worth $6,359,000 after purchasing an additional 27,518 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.